Quick Answer
Greenwich LifeSciences, Inc. reported Net Income of -$15.79 million for fiscal year 2024.
Greenwich LifeSciences, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$15.79M -77.6% |
-$8.89M -13.6% |
-$7.83M -71.2% |
-$4.57M -145.3% |
-$1.86M +45.6% |
-$3.43M |
| Diluted EPS | -$1.21 -75.4% |
-$0.69 -13.1% |
-$0.61 | — | — | — |
| Total Assets | $4.09M -41.5% |
$6.99M -48.1% |
$13.48M -50.5% |
$27.22M -5.1% |
$28.68M +107419.8% |
$26.7K |
| Cash and Equivalents | $4.09M -41.5% |
$6.99M -48.1% |
$13.47M -50.5% |
$27.20M -5.1% |
$28.66M +419217.8% |
$6.8K |
| Stockholders Equity | $2.53M -62.2% |
$6.70M -49.3% |
$13.21M -50.8% |
$26.83M -2.9% |
$27.63M +2146.1% |
-$1.35M +86.7% |
| R&D Expense | $12.95M +68.2% |
$7.70M +18.9% |
$6.48M +81.9% |
$3.56M +236.6% |
$1.06M -59.4% |
$2.61M |
| Operating Income | -$16.01M -71.7% |
-$9.33M -16.0% |
-$8.04M -74.9% |
-$4.60M -146.7% |
-$1.86M +45.6% |
-$3.43M |
| Shares Outstanding | 13.15M +2.4% |
12.85M +0.0% |
12.85M -2.3% |
13.15M +3.5% |
12.70M +50.2% |
8.46M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.15M | -55.6% | -3.1% |
| Diluted EPS | September 30, 2025 | -$0.30 | -50.0% | +0.0% |
| Total Assets | September 30, 2025 | $3.81M | -34.6% | +21.8% |
| Cash and Equivalents | September 30, 2025 | $3.81M | -34.6% | +21.8% |
| Stockholders Equity | September 30, 2025 | $2.18M | -56.1% | +51.8% |
| R&D Expense | September 30, 2025 | $3.52M | +53.6% | +0.4% |
| Operating Income | September 30, 2025 | -$4.17M | -53.0% | -3.2% |
| Shares Outstanding | September 30, 2025 | 13.79M | +4.9% | +2.4% |
- Greenwich LifeSciences, Inc. reported Net Income of -$15.79 million for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -77.6% in Net Income compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported Diluted EPS of $1.21 per share (loss) for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -75.4% in Diluted EPS compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported Total Assets of $4.09 million for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -41.5% in Total Assets compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported Cash and Equivalents of $4.09 million for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -41.5% in Cash and Equivalents compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported Stockholders Equity of $2.53 million for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -62.2% in Stockholders Equity compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported R&D Expense of $12.95 million for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed an increase of +68.2% in R&D Expense compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported Operating Income of -$16.01 million for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -71.7% in Operating Income compared to the prior fiscal year.
- Greenwich LifeSciences, Inc. reported Shares Outstanding of 13.15 million shares for fiscal year 2024.
- Greenwich LifeSciences, Inc. showed an increase of +2.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: